Conditions: Hodgkin Lymphoma
Keywords: HL idelalisib CAL-101 GS-1101 PI3K
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate.

Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable toxicity.

Detailed description:

Arms:
arm 1: Participants will receive up to 300 mg of idelalisib twice daily.

Interventions: intervention 1: Idelalisib
Intervention descriptions: intervention 1: Idelalisib tablets administered orally

Protocol document: